Proteomics

Dataset Information

0

Fecal metaproteomics reveals reduced gut inflammation and changed microbial metabolism following lifestyle-induced weight loss


ABSTRACT: Aims Gut microbiota-mediated inflammation promotes obesity-associated low-grade inflammation, which represents a hallmark of the metabolic syndrome (MetS). Lifestyle-induced weight loss (WL) is regarded as an efficient therapy to reverse MetS and to prevent disease progression. The objective of this study was to investigate if lifestyle-induced WL modulates the gut microbiome and its interaction with the host. Methods We analyzed and compared the fecal metaproteome of 33 individuals with MetS in a longitudinal study before and after lifestyle-induced WL in a well-defined cohort (ICTRP Trial Number: U1111-1158-3672). Results The 6-month WL intervention resulted in reduced BMI (-13.9%), increased insulin sensitivity (HOMA-IR; -53.70%) and reduced levels of circulating CRP (-66.86%), indicating MetS reversal. The metaprotein spectra of the host revealed a decrease of human proteins associated with gut inflammation and reduced abundance of human pancreatic alpha-amylase. Surprisingly, taxonomic analysis of the fecal metaproteome revealed only minor changes in the bacterial composition with an increase of low-abundant families (Desulfovibrionaceae, Leptospiraceae, Syntrophomonadaceae, Thermotogaceae, Verrucomicrobiaceae). Yet, we detected increased abundance of microbial metaprotein spectra that correspond to enhanced hydrolysis of complex carbohydrates (endoglucanase A, β-1,4-mannooligosaccharide phosphorylase, galactokinase, 5-keto-D-gluconate 5-reductase), indicating functional changes of the gut microbiome. Conclusions Our results indicate that lifestyle induced WL may improve interaction between the gut microbiome and the host in individuals with MetS, while bacterial composition remained almost stable. Metaproteome analysis of host proteins reveals reduced gut inflammation whereas microbial metaprotein spectra indicate functional changes towards degradation of complex carbohydrates. The filenames correspond to the ID of the patient (1-33), whereas “C” corresponds to baseline and “ABC” to weight loss.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): human gut metagenome  

TISSUE(S): Tissue Not Applicable To Dataset

DISEASE(S): Not Available

SUBMITTER: Robert Heyer  

LAB HEAD: Dirk Benndorf

PROVIDER: PXD020902 | Pride | 2021-04-19

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
ABC-01.dat Other
ABC-01.mgf Mgf
ABC-01.raw Raw
ABC-02.dat Other
ABC-02.mgf Mgf
Items per page:
1 - 5 of 198

Similar Datasets

2018-01-01 | S-EPMC5829308 | BioStudies
2019-01-01 | S-EPMC6470425 | BioStudies
2020-01-01 | S-EPMC7648414 | BioStudies
2016-01-01 | S-EPMC5006041 | BioStudies
2019-01-01 | S-EPMC6371617 | BioStudies
2015-01-01 | S-EPMC4631601 | BioStudies
2020-01-01 | S-EPMC7093822 | BioStudies
2019-01-01 | S-EPMC6839838 | BioStudies
2020-01-01 | S-EPMC7314955 | BioStudies
2020-01-01 | S-EPMC7562722 | BioStudies